Pharmaceutical compositions comprising a tolfenamic acid
Herriot Tabuteau, New York, NY (US)
Assigned to AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed by AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed on May 24, 2024, as Appl. No. 18/674,761.
Application 18/674,761 is a continuation of application No. 18/489,685, filed on Oct. 18, 2023, abandoned.
Application 18/489,685 is a continuation of application No. 18/051,656, filed on Nov. 1, 2022, granted, now 11,865,117, issued on Jan. 9, 2024.
Application 18/051,656 is a continuation in part of application No. 17/517,223, filed on Nov. 2, 2021, granted, now 11,510,927, issued on Nov. 29, 2022.
Application 17/517,223 is a continuation in part of application No. 17/205,936, filed on Mar. 18, 2021, granted, now 11,185,550, issued on Nov. 30, 2021.
Application 17/205,936 is a continuation in part of application No. 16/857,435, filed on Apr. 24, 2020, granted, now 10,987,358, issued on Apr. 27, 2021.
Application 17/517,223 is a continuation of application No. PCT/US2021/026027, filed on Apr. 6, 2021.
Claims priority of provisional application 63/006,023, filed on Apr. 6, 2020.
Prior Publication US 2024/0307408 A1, Sep. 19, 2024
1. A method of treating migraine, comprising administering to a human being in need thereof a combination of a tolfenamic acid, a rizatriptan, a bicarbonate, and a sulfobutylether-β-cyclodextrin (SBEβCD), wherein the human being is suffering from migraine pain or aura.